Kristopher K Frese
Overview
Explore the profile of Kristopher K Frese including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
4494
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Catozzi A, Peiris-Pages M, Humphrey S, Revill M, Morgan D, Roebuck J, et al.
bioRxiv
. 2024 Feb;
PMID: 38405859
Molecular subtypes of Small Cell Lung Cancer (SCLC) have been described based on differential expression of transcription factors (TFs) , and immune-related genes. We previously reported an additional subtype based...
2.
Pearsall S, Williamson S, Humphrey S, Hughes E, Morgan D, Garcia Marques F, et al.
J Thorac Oncol
. 2023 Jul;
18(10):1362-1385.
PMID: 37455012
Introduction: Vasculogenic mimicry (VM), the process of tumor cell transdifferentiation to endow endothelial-like characteristics supporting de novo vessel formation, is associated with poor prognosis in several tumor types, including SCLC....
3.
Chemi F, Pearce S, Clipson A, Hill S, Conway A, Richardson S, et al.
Nat Cancer
. 2022 Aug;
3(10):1260-1270.
PMID: 35941262
Small cell lung cancer (SCLC) is characterized by morphologic, epigenetic and transcriptomic heterogeneity. Subtypes based upon predominant transcription factor expression have been defined that, in mouse models and cell lines,...
4.
Simpson K, Stoney R, Frese K, Simms N, Rowe W, Pearce S, et al.
Nat Cancer
. 2022 Feb;
1(4):437-451.
PMID: 35121965
Although small cell lung cancer (SCLC) is treated as a homogeneous disease, biopsies and preclinical models reveal heterogeneity in transcriptomes and morphology. SCLC subtypes were recently defined by neuroendocrine transcription...
5.
Frizziero M, Kilgour E, Simpson K, Rothwell D, Moore D, Frese K, et al.
Clin Cancer Res
. 2022 Jan;
28(10):1999-2019.
PMID: 35091446
Poorly differentiated neuroendocrine carcinomas (PD-NEC) are rare cancers garnering interest as they become more commonly encountered in the clinic. This is due to improved diagnostic methods and the increasingly observed...
6.
Schenk M, Humphrey S, Hossain A, Revill M, Pearsall S, Lallo A, et al.
Nat Commun
. 2021 Nov;
12(1):6652.
PMID: 34789728
Small cell lung cancer (SCLC) has a 5-year survival rate of <7%. Rapid emergence of acquired resistance to standard platinum-etoposide chemotherapy is common and improved therapies are required for this...
7.
Frese K, Simpson K, Dive C
Cancer Cell
. 2021 Feb;
39(3):297-299.
PMID: 33577787
In this issue of Cancer Cell, Gay et al. describe a molecular classification of small cell lung cancers and extend prior studies that highlight the potential for personalized treatments. Notably,...
8.
Progress towards non-small-cell lung cancer models that represent clinical evolutionary trajectories
Hynds R, Frese K, Pearce D, Gronroos E, Dive C, Swanton C
Open Biol
. 2021 Jan;
11(1):200247.
PMID: 33435818
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide. Although advances are being made towards earlier detection and the development of impactful targeted therapies and immunotherapies, the...
9.
Pearsall S, Humphrey S, Revill M, Morgan D, Frese K, Galvin M, et al.
J Thorac Oncol
. 2020 Jul;
15(12):1836-1843.
PMID: 32721553
Introduction: Recent consensus defines four SCLC subtypes on the basis of transcription factor expression: ASCL1, NEUROD1, POU2F3, and YAP1. The rare YAP1 subtype is associated with "neuroendocrine (NE)-low" cells among...
10.
Ponz-Sarvise M, Corbo V, Tiriac H, Engle D, Frese K, Oni T, et al.
Clin Cancer Res
. 2019 Sep;
25(22):6742-6755.
PMID: 31492749
Purpose: is mutated in the majority of pancreatic ductal adenocarcinoma. MAPK and PI3K-AKT are primary KRAS effector pathways, but combined MAPK and PI3K inhibition has not been demonstrated to be...